Regulation and function of Rankl in arterial calcification

Current Pharmaceutical Design

Volumn 20, Issue 37, 2014, Pages 5853-5861

  Di Bartolo, Belinda A ^a   Kavurma, Mary M ^b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b HEART RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Arterial calcification; Osteoprotegerin (OPG); Receptor activator of nuclear factor B ligand (RANKL); Tumour necrosis factor related apoptosisinducing ligand (TRAIL)

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TNFSF11 PROTEIN, HUMAN;

ARTERY CALCIFICATION; ARTICLE; BLOOD VESSEL WALL; BONE REMODELING; CELL THERAPY; GENE CONTROL; GENE EXPRESSION; HUMAN; INFLAMMATORY CELL; NONHUMAN; REGULATORY MECHANISM; VASCULARIZATION; BLOOD VESSEL CALCIFICATION; GENETICS; METABOLISM;

HUMANS; RANK LIGAND; VASCULAR CALCIFICATION;

EID: 84911466832     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140212205455     Document Type: Article

References (113)

1. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation 2008; 117: 2938-48.
2. Kovacic JC, Fuster V. Vascular calcification, diabetes, and cardiovascular disease: connecting the dots. JACC. Cardiovascular Imaging 2012; 5: 367-9.
3. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol: JASN 2008; 19: 213-6.
4. Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am College Cardiol 2005; 46: 158-65.
5. Iribarren C, Sidney S, Sternfeld B, Browner WS. Calcification of the aortic arch: risk factors and association with coronary heart disease, stroke, and peripheral vascular disease. JAMA: J Am Med Assoc 2000; 283: 2810-5.
6. Allison MA, Hsi S, Wassel CL, et al. Calcified atherosclerosis in different vascular beds and the risk of mortality. Arteriosclerosis, Thrombosis, Vascular Biol 2012; 32: 140-6.
7. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol: JASN 2009; 20: 1453-64.
8. Snell-Bergeon JK, Budoff MJ, Hokanson JE. Vascular calcification in diabetes: mechanisms and implications. Curr Diabetes Reports 2013; 13: 391-402.
9. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O’Donnell CJ, Wilson PW. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcified Tissue Int 2001; 68: 271-6.
10. Chen NX, Moe SM. Vascular calcification: pathophysiology and risk factors. Curr Hypertension Reports 2012; 14: 228-37.
11. Moe SM, Chen NX. Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis. Pediatric nephrology 2003; 18: 969-75.
12. Doherty TM, Asotra K, Fitzpatrick LA, et al. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA 2003; 100: 11201-6.
13. Byon CH, Sun Y, Chen J, et al. Runx2-upregulated receptor activator of nuclear factor kappaB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arteriosclerosis, Thrombosis, Vascular Biol 2011; 31: 1387-96.
14. Morony S, Sage AP, Corbin T, Lu J, Tintut Y, Demer LL. Enhanced mineralization potential of vascular cells from SM22alpha-Rankl (tg) mice. Calcified Tissue Int 2012; 91: 379-86.
15. Ndip A, Williams A, Jude EB, et al The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. Diabetes 2011; 60: 2187-96.
16. Osako MK, Nakagami H, Koibuchi N, et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circulation Res 2010; 107: 466-75.
17. Panizo S, Cardus A, Encinas M, et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circulation Res 2009; 104: 1041-8.
18. Yuan LQ, Zhu JH, Wang HW, et al. RANKL is a downstream mediator for insulin-induced osteoblastic differentiation of vascular smooth muscle cells. PLoS One 2011; 6: e29037.
19. Guzman RJ. Clinical, cellular, and molecular aspects of arterial calcification. J Vasc Surg 2007; 45 Suppl A: A57-63.
20. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-9.
21. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
22. Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Communicat 1997; 234: 137-42.
23. Wong BR, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J biological chemistry 1997; 272: 25190-4.
24. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-602.
25. O’Brien CA. Control of RANKL gene expression. Bone 2010; 46: 911-9.
26. Itoh K, Udagawa N, Matsuzaki K, et al. Importance of membrane-or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. J bone and mineral research: the official J Am Soc Bone Mineral Res 2000; 15: 1766-75.
27. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-23.
28. Hikita A, Yana I, Wakeyama H, et al. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. J biological chemistry 2006; 281: 36846-55.
29. Lum L, Wong BR, Josien R, et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biological Chem 1999; 274: 13613-8.
30. Nagai M, Kyakumoto S, Sato N. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochemical Biophysical Res Communicat 2000; 269: 532-6.
31. Walsh NC, Alexander KA, Manning CA, et al. Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. Genes Immunity 2013; 14: 336-45.
32. Liu C, Walter TS, Huang P, et al. Structural and functional insights of RANKL-RANK interaction and signaling. J immunol 2010; 184: 6910-9.
33. Luan X, Lu Q, Jiang Y, et al. Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin. J immunol 2012; 189: 245-52.
34. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcified tissue international 2004; 74: 103-6.
35. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arteriosclerosis, thrombosis, Vascular Biol 2002; 22: 549-53.
36. Rucci N. Molecular biology of bone remodelling. Clin Cases Miner Bone Metab 2008; 5: 49-56.
37. Sobacchi C, Frattini A, Guerrini MM, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nature Genet 2007; 39: 960-2.
38. Guerrini MM, Sobacchi C, Cassani B, et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet 2008; 83: 64-76.
39. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA: the J Am Med Associat 2004; 292: 490-5.
40. Takayanagi H. New developments in osteoimmunology. Nature Rev Rheumatol 2012; 8: 684-9.
41. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biological Chem 2001; 276: 20659-72.
42. Sandberg WJ, Yndestad A, Oie E, et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arteriosclerosis, Thrombosis, Vascular Biol 2006; 26: 857-63.
43. Mosheimer BA, Kaneider NC, Feistritzer C, Sturn DH, Wiedermann CJ. Expression and function of RANK in human monocyte chemotaxis. Arthritis Rheum 2004; 50: 2309-16.
44. Schoppet M, Al-Fakhri N, Franke FE, et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg’s sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004; 89: 4104-12.
45. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21: 1998-2003.
46. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arteriosclerosis, thrombosis, and vascular biology 2003; 23: 489-94.
47. Morony S, Tintut Y, Zhang Z, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008; 117: 411-20.
48. Helas S, Goettsch C, Schoppet M, et al. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 2009; 175: 473-8.
49. Deuell KA, Callegari A, Giachelli CM, Rosenfeld ME, Scatena M. RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treated smooth muscle cells: dependence on IL-6 and TNF-alpha. J Vascular Res 2012; 49: 510-21.
50. Ma R, Xu J, Dong B, Kauther MD, Jager M, Wedemeyer C. Inhibition of osteoclastogenesis by RNA interference targeting RANK. BMC Musculoskelet Disord 2012; 13: 154.
51. Mochizuki A, Takami M, Miyamoto Y, et al. Cell adhesion signaling regulates RANK expression in osteoclast precursors. PLoS One 2012; 7: e48795.
52. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J clinical investigation 2005; 115: 1210-20.
53. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circulation research 2005; 97: 105-14.
54. Bucay N, Sarosi I, Dunstan CR, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-8.
55. Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000; 192: 463-74.
56. Callegari A, Coons ML, Ricks JL, et al. Bone marrow-or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification. Arterioscler Thromb Vasc Biol 2013; 33: 2491-500.
57. Braam LA, Dissel P, Gijsbers BL, et al. Assay for human matrix gla protein in serum: potential applications in the cardiovascular field. Arteriosclerosis, thrombosis, and vascular biology 2000; 20: 1257-61.
58. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81.
59. Mody N, Tintut Y, Radcliff K, Demer LL. Vascular calcification and its relation to bone calcification: possible underlying mechanisms. J nuclear cardiology: official publication Am Soc Nuclear Cardiol 2003; 10: 177-83.
60. Montagnana M, Lippi G, Danese E, Guidi GC. The role of osteoprotegerin in cardiovascular disease. Ann Med 2013; 45: 254-64.
61. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009; 204: 321-9.
62. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004; 95: 1046-57.
63. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631-7.
64. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-4.
65. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88: 1024-8.
66. Schoppet M, Schaefer JR, Hofbauer LC. Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation 2003; 107: e76; author reply e76.
67. Kavurma MM, Bennett MR. Expression, regulation and function of trail in atherosclerosis. Biochem Pharmacol 2008; 75: 1441-50.
68. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 2: 673-82.
69. Harith HH, Morris MJ, Kavurma MM. On the TRAIL of obesity and diabetes. Trends Endocrinol Metab 2013; 24(11): 578-87. doi: 10. 1016.
70. Azahri NS, Kavurma MM. Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand. Cell Mol Life Sci 2013; 70(19): 3617-29. doi: 10. 1007.
71. Yen ML, Tsai HF, Wu YY, Hwa HL, Lee BH, Hsu PN. TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation from monocyte/macrophage lineage precursor cells. Molecular immunology 2008; 45: 2205-13.
72. Yen ML, Hsu PN, Liao HJ, Lee BH, Tsai HF. TRAF-6 dependent signaling pathway is essential for TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation. PLoS One 2012; 7: e38048.
73. Liu X, Winrow VR, Horrocks M, Stevens CR. Differential expression of TRAIL and its receptors relative to calcification in AAA. Biochemical and biophysical research communications 2007; 358: 18-23.
74. Chasseraud M, Liabeuf S, Mozar A, et al. Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification. Therapeutic apheresis and dialysis: official peer-reviewed J Int Soc Apheresis, Japanese Soc Apheresis, Japanese Soc Dialysis Therap 2011; 15: 140-6.
75. Di Bartolo BA, Cartland SP, Harith HH, Bobryshev Y, Schoppet M, Kavurma MM. TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL. PLoS One 2013; 8(9): e74211. doi: 10. 1371.
76. Suda T, Udagawa N, Nakamura I, Miyaura C, Takahashi N. Modulation of osteoclast differentiation by local factors. Bone 1995; 17: 87S-91S.
77. Takahashi N, Yamana H, Yoshiki S, et al. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 1988; 122: 1373-82.
78. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999; 140: 3552-61.
79. Kanematsu M, Sato T, Takai H, Watanabe K, Ikeda K, Yamada Y. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J bone and mineral research: the official J Am Society Bone Mineral Res 2000; 15: 1321-9.
80. Nukaga J, Kobayashi M, Shinki T, et al. Regulatory effects of interleukin-1beta and prostaglandin E2 on expression of receptor activator of nuclear factor-kappaB ligand in human periodontal ligament cells. J Periodontol 2004; 75: 249-59.
81. Udagawa N, Takahashi N, Jimi E, et al. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone 1999; 25: 517-23.
82. Swanson C, Lorentzon M, Conaway HH, Lerner UH. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. Endocrinology 2006; 147: 3613-22.
83. Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J cell science 2006; 119: 1283-96.
84. Kitazawa R, Kitazawa S, Maeda S. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. Biochimica et biophysica acta 1999; 1445: 134-41.
85. Kitazawa S, Kajimoto K, Kondo T, Kitazawa R. Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. J cellular Biochem 2003; 89: 771-7.
86. Kitazawa R, Mori K, Yamaguchi A, Kondo T, Kitazawa S. Modulation of mouse RANKL gene expression by Runx2 and vitamin D3. J cellular Biochem 2008; 105: 1289-97.
87. Fu Q, Jilka RL, Manolagas SC, O’Brien CA. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J biological Chem 2002; 277: 48868-75.
88. Kim S, Yamazaki M, Shevde NK, Pike JW. Transcriptional control of receptor activator of nuclear factor-kappaB ligand by the protein kinase A activator forskolin and the transmembrane glycoprotein 130-activating cytokine, oncostatin M, is exerted through multiple distal enhancers. Molecular Endocrinol 2007; 21: 197-214.
89. O’Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1, 2 5-dihydroxy vitamin D3 or parathyroid hormone. J Biological Chem 1999; 274: 19301-8.
90. Roccisana JL, Kawanabe N, Kajiya H, Koide M, Roodman GD, Reddy SV. Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cells. J biological chemistry 2004; 279: 10500-7.
91. Ishida A, Fujita N, Kitazawa R, Tsuruo T. Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone. J biological chemistry 2002; 277: 26217-24.
92. Kim HH, Shin HS, Kwak HJ, et al. RANKL regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. FASEB journal: official publication Federation Am Soc Exp Biol 2003; 17: 2163-5.
93. Okada T, Akikusa S, Okuno H, Kodaka M. Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. Clinical Experimental Metastasis 2003; 20: 639-46.
94. Bishop KA, Coy HM, Nerenz RD, Meyer MB, Pike JW. Mouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region. J Biological Chem 2011; 286: 20880-91.
95. Ju JH, Cho ML, Moon YM, et al. IL-23 induces receptor activator of NF-kappaB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model. J Immunol 2008; 181: 1507-18.
96. Page G, Miossec P. RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum 2005; 52: 2307-12.
97. Tseng W, Graham LS, Geng Y, et al. PKA-induced receptor activator of NF-kappaB ligand (RANKL) expression in vascular cells mediates osteoclastogenesis but not matrix calcification. J Biological Chem 2010; 285: 29925-31.
98. Cosson E, Valensi P, Laude D, Mesangeau D, Dabire H. Arterial stiffness and the autonomic nervous system during the development of Zucker diabetic fatty rats. Diabetes Metabol 2009; 35: 364-70.
99. Siddappa R, Mulder W, Steeghs I, et al. cAMP/PKA signaling inhibits osteogenic differentiation and bone formation in rodent models. Tissue engineering. Part A 2009; 15: 2135-43.
100. Thomas SR, Witting PK, Drummond GR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxidants Redox Signaling 2008; 10: 1713-65.
101. Byon CH, Javed A, Dai Q, et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biological Chem 2008; 283: 15319-27.
102. Kim YM, Lee YM, Kim HS, Kim JD, Choi Y, Kim KW, Lee SY, Kwon YG. TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. J Biological Chem 2002; 277: 6799-805.
103. Min JK, Kim YM, Kim SW, et al. TNF-related activation-induced cytokine enhances leukocyte adhesiveness: induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-kappaB activation in endothelial cells. J Immunol 2005; 175: 531-40.
104. Min JK, Cho YL, Choi JH, et al. Receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice. Blood 2007; 109: 1495-502.
105. Grainger DJ. TGF-beta and atherosclerosis in man. Cardiovascular Research 2007; 74: 213-22.
106. Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT. Activated T lymphocytes support osteoclast formation in vitro. Biochemical and biophysical research communications 1999; 265: 144-50.
107. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-9.
108. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995; 83: 803-12.
109. Seno T, Hamaguchi M, Ashihara E, et al. 15-Deoxy-Delta(1)(2), (1) (4) prostaglandin J(2) reduces the formation of atherosclerotic lesions in apolipoprotein E knockout mice. PLoS One 2011; 6: e25541.
110. Fionda C, Nappi F, Piccoli M, Frati L, Santoni A, Cippitelli M. 15-deoxy-Delta12, 14-prostaglandin J2 negatively regulates rankl gene expression in activated T lymphocytes: role of NF-kappaB and early growth response transcription factors. J Immunol 2007; 178: 4039-50.
111. Blaschke F, Bruemmer D, Law RE. Egr-1 is a major vascular pathogenic transcription factor in atherosclerosis and restenosis. Rev Endocrine Metabol Disorders 2004; 5: 249-54.
112. Grigoriadis AE, Wang ZQ, Cecchini MG, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994; 266: 443-8.
113. Park HJ, Park OJ, Shin J. Receptor activator of NF-kappaB ligand enhances the activity of macrophages as antigen presenting cells. Exp Mol Med 2005; 37: 524-32.